DOCSLIB.ORG

Figure. S1 the Quantities in the Chosen Columns Vs. the Soft Threshold Power

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Figure. S1 the Quantities in the Chosen Columns Vs. the Soft Threshold Power Figure. S1 The quantities in the chosen columns vs. the soft threshold power Figure S2. Heat map of differentially expressed genes. X-axis shows the cluster of cases (cluster 1) and controls (cluster 2), Y-axis shows the dendrogram of differentially expressed genes. Genes 2018, 9, x; doi: FOR PEER REVIEW www.mdpi.com/journal/genes Genes 2018, 9, x FOR PEER REVIEW 2 of 39 Figure. S3 a. Expression level of SLC32A1 between cases and controls Genes 2018, 9, x FOR PEER REVIEW 3 of 39 b. Expression level of HINT1 between cases and controls Genes 2018, 9, x FOR PEER REVIEW 4 of 39 c. Expression level of IFITM3 between cases and controls Genes 2018, 9, x FOR PEER REVIEW 5 of 39 d. Expression level of RELN between cases and controls Genes 2018, 9, x FOR PEER REVIEW 6 of 39 Figure. S4 Protein-Protein Interaction Network structure of detected modules a. Module yellow Genes 2018, 9, x FOR PEER REVIEW 7 of 39 b. Module turquoise Genes 2018, 9, x FOR PEER REVIEW 8 of 39 c. Module blue Genes 2018, 9, x FOR PEER REVIEW 9 of 39 d. Module brown Genes 2018, 9, x FOR PEER REVIEW 10 of 39 Table S1. Sample demographics Sex (% N Age pH PMI RIN Subtype MoodDx Substance Dx Suicide Antidepr Tox F) 7 BN 2 AN-BN ED 15 86.7 40.1 ±8.1 6.2 ±0.2 32.3 ±19.5 7.57 ±0.88 86.70% 53.30% 73.30% 66.70% 3 AN 3 NOS Control 102 20.5 42.5 ±17.2 6.6±0.3 27.2±14.8 8.3±0.69 Abbreviations: AN, anorexia nervosa (restricting); AN-BN, anorexia nervosa, binge–purge type; AntidepressTox, percentage of cases on antidepressants at the time of death as measured by blood/brain toxicology; BN, bulimia nervosa; ED, eating disorder; MoodDx, presence of comorbid Axis I mood disorder diagnosis; NOS, eating disorder not otherwise specified; pH, brain pH; PMI, postmortem interval in hours; RIN, RNA integrity number; Substance Dx, presence of comorbid Axis I substance use disorder. All numerical cells are mean±s.d. Genes 2018, 9, x FOR PEER REVIEW 11 of 39 Table S2. Differentially expressed genes Expression genname logFC AveExpr t P.Value adj.P.Val B TNFRSF6B 0.81 8.01 6.15 1.07E-08 1.42E-04 9.47 TSHZ2 0.47 8.69 5.44 2.84E-07 9.35E-04 6.48 AP1G2 0.45 8.50 5.16 1.01E-06 1.37E-03 5.33 HYOU1 0.49 9.08 5.15 1.05E-06 1.37E-03 5.29 ELK1 0.53 9.76 5.13 1.14E-06 1.37E-03 5.21 CHTF18 0.27 7.74 5.11 1.23E-06 1.37E-03 5.15 IGSF9B 0.41 8.00 5.07 1.49E-06 1.52E-03 4.97 COL4A1 0.59 8.28 5.02 1.80E-06 1.58E-03 4.80 SIN3B 0.51 8.86 4.78 4.97E-06 2.58E-03 3.88 PPP1R10 0.38 8.40 4.77 5.21E-06 2.58E-03 3.83 ULK3 0.35 8.11 4.77 5.26E-06 2.58E-03 3.83 DGCR2 0.47 9.63 4.71 6.78E-06 3.21E-03 3.60 ABCA7 0.37 7.91 4.67 7.84E-06 3.26E-03 3.46 TTC14 0.46 9.21 4.67 8.02E-06 3.26E-03 3.44 LOC146177 0.26 7.76 4.66 8.15E-06 3.26E-03 3.43 Up-regulation ST6GALNAC6 0.58 10.51 4.55 1.31E-05 4.69E-03 3.00 PTCHD1 0.34 8.69 4.51 1.56E-05 5.27E-03 2.84 SRC 0.40 9.07 4.49 1.64E-05 5.28E-03 2.80 PARC 0.33 8.07 4.44 2.03E-05 5.78E-03 2.61 CSDA 0.78 8.90 4.44 2.06E-05 5.78E-03 2.59 SFRS14 0.34 8.30 4.42 2.20E-05 5.78E-03 2.53 LOC654342 0.34 7.85 4.42 2.23E-05 5.78E-03 2.52 CHMP1A 0.40 9.21 4.37 2.64E-05 6.36E-03 2.37 HS.490981 0.40 8.38 4.37 2.65E-05 6.36E-03 2.36 DGKG 0.27 7.80 4.36 2.73E-05 6.36E-03 2.34 LAMC1 0.33 8.99 4.36 2.77E-05 6.36E-03 2.33 MTHFR 0.29 7.93 4.36 2.79E-05 6.36E-03 2.32 ZNF562 0.27 8.59 4.33 3.12E-05 6.89E-03 2.22 CACNA1A 0.55 8.29 4.33 3.13E-05 6.89E-03 2.22 GADD45B 0.56 7.92 4.29 3.65E-05 7.81E-03 2.08 HELZ 0.30 8.96 4.29 3.71E-05 7.81E-03 2.06 Genes 2018, 9, x FOR PEER REVIEW 12 of 39 CHERP 0.22 8.03 4.29 3.72E-05 7.81E-03 2.06 LOC644931 0.51 8.44 4.27 4.03E-05 8.07E-03 1.99 SHC1 0.42 9.14 4.26 4.13E-05 8.07E-03 1.97 HS.388347 0.32 8.26 4.26 4.19E-05 8.07E-03 1.95 IFT140 0.26 7.85 4.25 4.21E-05 8.07E-03 1.95 CACNA1C 0.26 8.04 4.22 4.82E-05 8.52E-03 1.83 ZER1 0.38 8.73 4.21 4.92E-05 8.52E-03 1.81 GNAO1 0.63 11.80 4.21 5.05E-05 8.52E-03 1.78 ADCY6 0.25 8.03 4.20 5.24E-05 8.52E-03 1.75 NPIP 0.47 10.30 4.19 5.35E-05 8.52E-03 1.73 RNF40 0.27 8.56 4.16 6.09E-05 9.37E-03 1.62 ANKRD20A1 0.62 10.26 4.15 6.19E-05 9.42E-03 1.60 BAG4 0.35 8.07 4.11 7.20E-05 1.05E-02 1.47 EXTL3 0.44 9.57 4.08 8.30E-05 1.16E-02 1.34 PHYHIP 0.57 9.27 4.08 8.34E-05 1.16E-02 1.33 RGS11 0.32 8.07 4.05 9.01E-05 1.23E-02 1.26 GNB2 0.27 7.94 4.05 9.17E-05 1.24E-02 1.25 TUBGCP6 0.20 7.77 4.05 9.25E-05 1.24E-02 1.24 SLC38A11 0.34 8.28 4.03 9.88E-05 1.27E-02 1.18 OGDH 0.44 9.07 4.02 1.04E-04 1.29E-02 1.14 FURIN 0.18 7.75 4.01 1.05E-04 1.29E-02 1.13 NARFL 0.27 8.30 4.00 1.11E-04 1.33E-02 1.07 ADAM11 0.41 8.99 3.99 1.14E-04 1.35E-02 1.05 HS.34558 0.26 8.20 3.99 1.15E-04 1.35E-02 1.04 CEBPD 0.66 9.28 3.98 1.19E-04 1.35E-02 1.02 HS.181500 0.31 8.32 3.98 1.20E-04 1.35E-02 1.00 MT1M 0.86 9.40 3.98 1.21E-04 1.35E-02 1.00 RSAD1 0.27 7.90 3.97 1.22E-04 1.35E-02 0.99 CELSR3 0.38 9.92 3.97 1.23E-04 1.35E-02 0.99 BZRAP1 0.44 9.50 3.97 1.24E-04 1.35E-02 0.98 LOC729008 0.23 7.71 3.97 1.25E-04 1.35E-02 0.97 ST5 0.26 8.01 3.96 1.27E-04 1.36E-02 0.96 SLC9A5 0.26 7.91 3.95 1.34E-04 1.37E-02 0.91 Genes 2018, 9, x FOR PEER REVIEW 13 of 39 COLQ 0.21 8.06 3.95 1.35E-04 1.37E-02 0.90 MBOAT7 0.45 9.48 3.94 1.36E-04 1.37E-02 0.90 SMARCD3 0.27 8.51 3.94 1.36E-04 1.37E-02 0.90 B4GALNT4 0.47 8.95 3.94 1.37E-04 1.38E-02 0.89 ANKFY1 0.21 8.07 3.94 1.39E-04 1.38E-02 0.88 CIC 0.28 8.36 3.94 1.40E-04 1.38E-02 0.87 LOC728734 0.57 10.83 3.93 1.43E-04 1.39E-02 0.85 TRIM52 0.23 8.12 3.91 1.51E-04 1.44E-02 0.80 ADAMTS9 0.34 7.78 3.91 1.53E-04 1.44E-02 0.79 PKD1 0.59 9.32 3.91 1.55E-04 1.44E-02 0.78 MBTPS1 0.33 8.16 3.91 1.55E-04 1.44E-02 0.78 SOHLH1 0.43 8.42 3.90 1.57E-04 1.44E-02 0.77 RIMS4 0.43 8.77 3.90 1.59E-04 1.45E-02 0.76 LPPR2 0.41 8.92 3.90 1.60E-04 1.45E-02 0.75 RAD9A 0.22 7.97 3.90 1.63E-04 1.46E-02 0.74 RFNG 0.42 9.60 3.89 1.64E-04 1.46E-02 0.73 PPP2R5B 0.27 9.40 3.89 1.66E-04 1.47E-02 0.72 SYMPK 0.39 8.14 3.88 1.72E-04 1.50E-02 0.68 ANGPT2 0.37 7.82 3.85 1.89E-04 1.61E-02 0.60 C19ORF28 0.21 7.92 3.84 1.97E-04 1.65E-02 0.57 CCDC109A 0.21 8.04 3.84 2.01E-04 1.67E-02 0.55 SERPING1 0.29 7.94 3.84 2.02E-04 1.67E-02 0.54 USP35 0.19 7.75 3.83 2.07E-04 1.70E-02 0.52 UNKL 0.30 8.12 3.82 2.13E-04 1.74E-02 0.49 LOC441268 0.37 8.82 3.82 2.14E-04 1.74E-02 0.49 PTP4A2 0.37 8.85 3.81 2.18E-04 1.75E-02 0.48 FLJ33534 0.21 7.73 3.81 2.18E-04 1.75E-02 0.48 BTBD9 0.30 7.95 3.81 2.24E-04 1.77E-02 0.45 ADCY6 0.29 8.67 3.80 2.30E-04 1.79E-02 0.43 TUFT1 0.24 8.15 3.80 2.31E-04 1.79E-02 0.42 ZFX 0.16 7.69 3.79 2.34E-04 1.80E-02 0.41 DDEFL1 0.30 8.49 3.79 2.41E-04 1.82E-02 0.38 UPF1 0.32 8.56 3.79 2.41E-04 1.82E-02 0.38 Genes 2018, 9, x FOR PEER REVIEW 14 of 39 CLASP1 0.33 10.32 3.78 2.45E-04 1.82E-02 0.37 YTHDF1 0.23 9.54 3.78 2.46E-04 1.82E-02 0.37 GCAT 0.33 8.73 3.78 2.48E-04 1.82E-02 0.36 LOC650580 0.33 7.82 3.78 2.50E-04 1.82E-02 0.35 PAPD5 0.39 8.76 3.77 2.52E-04 1.82E-02 0.35 MLL 0.21 8.28 3.77 2.55E-04 1.82E-02 0.33 LOC440359 0.41 7.93 3.76 2.60E-04 1.83E-02 0.32 TAOK2 0.38 8.23 3.75 2.70E-04 1.86E-02 0.28 TBC1D3G 0.23 7.90 3.75 2.72E-04 1.86E-02 0.28 TEF 0.46 9.72 3.75 2.77E-04 1.89E-02 0.26 SLC39A14 0.25 8.17 3.74 2.80E-04 1.89E-02 0.25 PTPRA 0.40 9.87 3.74 2.81E-04 1.89E-02 0.25 DLG4 0.72 11.79 3.74 2.85E-04 1.90E-02 0.23 COL6A1 0.41 8.61 3.73 2.91E-04 1.91E-02 0.22 TTC14 0.34 9.29 3.73 2.92E-04 1.91E-02 0.21 EDN1 0.44 7.95 3.73 2.96E-04 1.92E-02 0.20 MAPK11 0.38 8.41 3.72 3.08E-04 1.94E-02 0.17 COL11A1 0.30 8.27 3.72 3.10E-04 1.94E-02 0.16 LOC728452 0.25 7.75 3.72 3.11E-04 1.94E-02 0.16 IL18BP 0.27 7.98 3.71 3.12E-04 1.94E-02 0.15 RORB 0.50 9.14 3.71 3.16E-04 1.94E-02 0.14 CLIP2 0.42 9.71 3.71 3.17E-04 1.94E-02 0.14 DPP9 0.38 8.58 3.70 3.25E-04 1.95E-02 0.12 CHD8 0.40 9.67 3.70 3.31E-04 1.97E-02 0.10 HDAC5 0.30 8.42 3.70 3.31E-04 1.97E-02 0.10 NRBP1 0.21 7.86 3.70 3.33E-04 1.97E-02 0.10 FLJ37078 0.42 8.43 3.70 3.33E-04 1.97E-02 0.10 RPIA 0.23 8.12 3.69 3.37E-04 1.97E-02 0.09 FGF17 0.29 7.75 3.69 3.40E-04 1.97E-02 0.08 YWHAE 0.56 8.98 3.69 3.40E-04 1.97E-02 0.08 LOC613037 0.61 11.76 3.69 3.41E-04 1.97E-02 0.08 RANBP10 0.19 8.19 3.69 3.45E-04 1.98E-02 0.07 PBX1 0.17 7.72 3.68 3.55E-04 2.00E-02 0.04 Genes 2018, 9, x FOR PEER REVIEW 15 of 39 SCARA3 0.28 7.85 3.68 3.58E-04 2.00E-02 0.03 SYT7 0.48 10.48 3.67 3.59E-04 2.00E-02 0.03 MKL1 0.23 8.38 3.67 3.60E-04 2.00E-02 0.03 GADD45A 0.40 9.29 3.67 3.66E-04 2.01E-02 0.01 KLHL18 0.20 7.96 3.67 3.66E-04 2.01E-02 0.01 NAT9 0.20 8.76 3.67 3.66E-04 2.01E-02 0.01 NOL5A 0.36 9.96 3.66 3.71E-04 2.01E-02 0.00 TNFRSF25 0.56 9.30 3.66 3.72E-04 2.01E-02 0.00 KIAA0460 0.24 7.93 3.66 3.80E-04 2.03E-02 -0.02 AKAP8L 0.42 8.74 3.66 3.81E-04 2.03E-02 -0.02 MEG3 0.49 11.11 3.66 3.83E-04 2.04E-02 -0.03 ZBTB16 0.40 9.01 3.65 3.86E-04 2.05E-02 -0.04 GRB2 0.24 8.67 3.65 3.94E-04 2.08E-02 -0.05 BAT2 0.42 9.35 3.64 4.00E-04 2.08E-02 -0.07 KIAA0664 0.36 8.66 3.63 4.12E-04 2.13E-02 -0.09 TAOK1 0.37 8.33 3.63 4.15E-04 2.14E-02 -0.10 SS18L1 0.27 8.91 3.63 4.18E-04 2.14E-02 -0.11 ATG16L2 0.23 8.06 3.63 4.23E-04 2.14E-02 -0.11 LIMK1 0.30 8.10 3.62 4.36E-04 2.18E-02 -0.14 GOLGA8A 0.48 8.15 3.62 4.37E-04 2.18E-02 -0.14 RN7SK 0.49 8.04 3.62 4.41E-04 2.18E-02 -0.15 ICAM2 0.40 8.83 3.60 4.58E-04 2.23E-02 -0.19 MEIS3 0.27 7.95 3.60 4.61E-04 2.23E-02 -0.19 STK38 0.25 8.41 3.60 4.70E-04 2.25E-02 -0.21 MFHAS1 0.22 7.83 3.59 4.82E-04 2.30E-02 -0.23 TYW3 0.27 8.35 3.59 4.86E-04 2.31E-02 -0.24 LOC91461 0.26 8.22 3.58 4.91E-04 2.32E-02 -0.25 ATXN7L3 0.45 10.58 3.58 5.07E-04 2.35E-02 -0.28 MKNK1 0.29 8.81 3.57 5.08E-04 2.35E-02 -0.28 NUPR1 0.32 8.31 3.57 5.14E-04 2.36E-02 -0.29 FLJ25006 0.28 8.58 3.57 5.14E-04 2.36E-02 -0.29 COL23A1 0.18 7.85 3.56 5.25E-04 2.40E-02 -0.31 APLP1 0.63 10.04 3.56 5.26E-04 2.40E-02 -0.31 Genes 2018, 9, x FOR PEER REVIEW 16 of 39 ST5 0.29 8.04 3.56 5.30E-04
Load more

Recommended publications
  • An Order Estimation Based Approach to Identify Response Genes
    AN ORDER ESTIMATION BASED APPROACH TO IDENTIFY RESPONSE GENES FOR MICRO ARRAY TIME COURSE DATA A Thesis Presented to The Faculty of Graduate Studies of The University of Guelph by ZHIHENG LU In partial fulfilment of requirements for the degree of Doctor of Philosophy September, 2008 © Zhiheng Lu, 2008 Library and Bibliotheque et 1*1 Archives Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington Ottawa ON K1A0N4 Ottawa ON K1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-47605-5 Our file Notre reference ISBN: 978-0-494-47605-5 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library permettant a la Bibliotheque et Archives and Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par Plntemet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans loan, distribute and sell theses le monde, a des fins commerciales ou autres, worldwide, for commercial or non­ sur support microforme, papier, electronique commercial purposes, in microform, et/ou autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in et des droits moraux qui protege cette these. this thesis. Neither the thesis Ni la these ni des extraits substantiels de nor substantial extracts from it celle-ci ne doivent etre imprimes ou autrement may be printed or otherwise reproduits sans son autorisation.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Sequence Analysis of Familial Neurodevelopmental Disorders
    SEQUENCE ANALYSIS OF FAMILIAL NEURODEVELOPMENTAL DISORDERS by Joseph Mark Tilghman A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland December 2020 © 2020 Joseph Tilghman All Rights Reserved Abstract: In the practice of human genetics, there is a gulf between the study of Mendelian and complex inheritance. When diagnosis of families affected by presumed monogenic syndromes is undertaken by genomic sequencing, these families are typically considered to have been solved only when a single gene or variant showing apparently Mendelian inheritance is discovered. However, about half of such families remain unexplained through this approach. On the other hand, common regulatory variants conferring low risk of disease still predominate our understanding of individual disease risk in complex disorders, despite rapidly increasing access to rare variant genotypes through sequencing. This dissertation utilizes primarily exome sequencing across several developmental disorders (having different levels of genetic complexity) to investigate how to best use an individual’s combination of rare and common variants to explain genetic risk, phenotypic heterogeneity, and the molecular bases of disorders ranging from those presumed to be monogenic to those known to be highly complex. The study described in Chapter 2 addresses putatively monogenic syndromes, where we used exome sequencing of four probands having syndromic neurodevelopmental disorders from an Israeli-Arab founder population to diagnose recessive and dominant disorders, highlighting the need to consider diverse modes of inheritance and phenotypic heterogeneity. In the study described in Chapter 3, we address the case of a relatively tractable multifactorial disorder, Hirschsprung disease.
    [Show full text]
  • Predicting Clinical Response to Treatment with a Soluble Tnf-Antagonist Or Tnf, Or a Tnf Receptor Agonist
    (19) TZZ _ __T (11) EP 2 192 197 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.06.2010 Bulletin 2010/22 C12Q 1/68 (2006.01) (21) Application number: 08170119.5 (22) Date of filing: 27.11.2008 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AT BE BG CH CY CZ DE DK EE ES FI FR GB GR yet been filed HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Habets, Winand Designated Extension States: Life Science Patents AL BA MK RS PO Box 5096 6130 PB Sittard (NL) (71) Applicant: Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg 1081 HV Amsterdam (NL) (54) Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist (57) The invention relates to methods for predicting a clinical response to a therapy with a soluble TNF antagonist, TNF or a TNF receptor agonist and a kit for use in said methods. EP 2 192 197 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 192 197 A1 Description [0001] The invention relates to methods for predicting a clinical response to a treatment with a soluble TNF antagonist, with TNF or a TNF receptor agonist using expression levels of genes of the Type I INF pathway and a kit for use in said 5 methods. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with a soluble TNF antagonist, TNF or a TNF receptor agonist.
    [Show full text]
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
    [Show full text]
  • Supplementary Material
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Page 1 / 45 SUPPLEMENTARY MATERIAL Appendix A1: Neuropsychological protocol. Appendix A2: Description of the four cases at the transitional stage. Table A1: Clinical status and center proportion in each batch. Table A2: Complete output from EdgeR. Table A3: List of the putative target genes. Table A4: Complete output from DIANA-miRPath v.3. Table A5: Comparison of studies investigating miRNAs from brain samples. Figure A1: Stratified nested cross-validation. Figure A2: Expression heatmap of miRNA signature. Figure A3: Bootstrapped ROC AUC scores. Figure A4: ROC AUC scores with 100 different fold splits. Figure A5: Presymptomatic subjects probability scores. Figure A6: Heatmap of the level of enrichment in KEGG pathways. Kmetzsch V, et al. J Neurol Neurosurg Psychiatry 2021; 92:485–493. doi: 10.1136/jnnp-2020-324647 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Appendix A1. Neuropsychological protocol The PREV-DEMALS cognitive evaluation included standardized neuropsychological tests to investigate all cognitive domains, and in particular frontal lobe functions. The scores were provided previously (Bertrand et al., 2018). Briefly, global cognitive efficiency was evaluated by means of Mini-Mental State Examination (MMSE) and Mattis Dementia Rating Scale (MDRS). Frontal executive functions were assessed with Frontal Assessment Battery (FAB), forward and backward digit spans, Trail Making Test part A and B (TMT-A and TMT-B), Wisconsin Card Sorting Test (WCST), and Symbol-Digit Modalities test.
    [Show full text]
  • MIRA-Assisted Microarray Analysis, a New Technology for The
    Research Article MIRA-Assisted Microarray Analysis, a New Technology for the Determination of DNA Methylation Patterns, Identifies Frequent Methylation of Homeodomain-Containing Genes in Lung Cancer Cells Tibor Rauch,1 Hongwei Li,1 Xiwei Wu,2 and Gerd P. Pfeifer1 Divisions of 1Biology and 2Biomedical Informatics, Beckman Research Institute of the City of Hope, Duarte, California Abstract hypermethylation generally leads to inactivation of gene expres- We present a straightforward and comprehensive approach sion, this epigenetic alteration is considered to be a key mechanism for DNA methylation analysis in mammalian genomes. The for long-term silencing of tumor suppressor genes. The importance methylated-CpG island recovery assay (MIRA), which is based of promoter methylation in functional inactivation of lung cancer on the high affinity of the MBD2/MBD3L1 complex for suppressor genes is becoming increasingly recognized. It is methylated DNA, has been used to detect cell type–dependent estimated that between 0.5% and 3% of all genes carrying CpG- differences in DNA methylation on a microarray platform. The rich promoter sequences (so-called CpG islands) may be silenced procedure has been verified and applied to identify a series of by DNA methylation in lung cancer (1, 11). This means that there novel candidate lung tumor suppressor genes and potential are most likely several hundred genes that are incapacitated by this DNA methylation markers that contain methylated CpG pathway. Some of these genes may be bona fide tumor suppressor islands. One gene of particular interest was DLEC1, located genes, but in other cases, the methylation event may be a at a commonly deleted area on chromosome 3p22-p21.3, consequence of gene silencing or may somehow be associated with which was frequently methylated in primary lung cancers and tumor formation rather than being a cause of tumorigenesis.
    [Show full text]
  • Arnau Soler2019.Pdf
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Genetic responses to environmental stress underlying major depressive disorder Aleix Arnau Soler Doctor of Philosophy The University of Edinburgh 2019 Declaration I hereby declare that this thesis has been composed by myself and that the work presented within has not been submitted for any other degree or professional qualification. I confirm that the work submitted is my own, except where work which has formed part of jointly-authored publications has been included. My contribution and those of the other authors to this work are indicated below. I confirm that appropriate credit has been given within this thesis where reference has been made to the work of others. I composed this thesis under guidance of Dr. Pippa Thomson. Chapter 2 has been published in PLOS ONE and is attached in the Appendix A, chapter 4 and chapter 5 are published in Translational Psychiatry and are attached in the Appendix C and D, and I expect to submit chapter 6 as a manuscript for publication.
    [Show full text]
  • Kinesin-Binding Protein Remodels the Kinesin Motor to Prevent Microtubule-Binding
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.02.446814; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Kinesin-binding protein remodels the kinesin motor to prevent microtubule-binding April L. Solon1*, Zhenyu Tan2,3*, Katherine L. Schutt4, Lauren Jepsen5, Sarah E. Haynes6, Alexey I. Nesvizhskii6,7, David Sept5, Jason Stumpff4, Ryoma Ohi1#, and Michael A. Cianfrocco3,8# 1Department of Cell and Developmental Biology, University of Michigan; 2Department of Biophysics, University of Michigan; 3Life Sciences Institute, University of Michigan; 4Department of Molecular Physiology and Biophysics, University of Vermont; 5Department of Biomedical Engineering, University of Michigan; 6Department of Pathology, University of Michigan; 7Department of Computational Medicine and Bioinformatics, University of Michigan; 8Department of Biological Chemistry, University of Michigan. *These authors contributed equally to this work. #For correspondence: [email protected] & [email protected] ABSTRACT Kinesins are tightly regulated in space and time to control their activation in the absence of cargo-binding. Kinesin-binding protein (KIFBP) was recently discovered to bind the catalytic motor heads of 8 of the 45 known kinesin superfamily members and inhibit binding to microtubules. In humans, mutation of KIFBP gives rise to Goldberg-Shprintzen syndrome (GOSHS), but the kinesin(s) that is misregulated to produce clinical features of the disease is not known. Understanding the structural mechanism by which KIFBP selects its kinesin binding partners will be key to unlocking this knowledge.
    [Show full text]
  • 1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression
    SUPPLEMENTAL DATA Figure S1. Poly I:C induces IFN-β expression and signaling. Fibroblasts were incubated in media with or without Poly I:C for 24 h. RNA was isolated and processed for microarray analysis. Genes showing >2-fold up- or down-regulation compared to control fibroblasts were analyzed using Ingenuity Pathway Analysis Software (Red color, up-regulation; Green color, down-regulation). The transcripts with known gene identifiers (HUGO gene symbols) were entered into the Ingenuity Pathways Knowledge Base IPA 4.0. Each gene identifier mapped in the Ingenuity Pathways Knowledge Base was termed as a focus gene, which was overlaid into a global molecular network established from the information in the Ingenuity Pathways Knowledge Base. Each network contained a maximum of 35 focus genes. 1 Figure S2. The overlap of genes regulated by Poly I:C and by IFN. Bioinformatics analysis was conducted to generate a list of 2003 genes showing >2 fold up or down- regulation in fibroblasts treated with Poly I:C for 24 h. The overlap of this gene set with the 117 skin gene IFN Core Signature comprised of datasets of skin cells stimulated by IFN (Wong et al, 2012) was generated using Microsoft Excel. 2 Symbol Description polyIC 24h IFN 24h CXCL10 chemokine (C-X-C motif) ligand 10 129 7.14 CCL5 chemokine (C-C motif) ligand 5 118 1.12 CCL5 chemokine (C-C motif) ligand 5 115 1.01 OASL 2'-5'-oligoadenylate synthetase-like 83.3 9.52 CCL8 chemokine (C-C motif) ligand 8 78.5 3.25 IDO1 indoleamine 2,3-dioxygenase 1 76.3 3.5 IFI27 interferon, alpha-inducible
    [Show full text]
  • A Case of a Boy with SOD and 7Q11.23 Microduplication Syndrome
    International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 – 6718, ISSN (Print): 2319 – 670X www.ijpsi.org Volume 6 Issue 9 ‖ September 2017 ‖ PP. 30-36 A case of a boy with SOD and 7q11.23 microduplication syndrome Ani Aroyo1, Iva Stoeva1,Gergana Stancheva2, Daniela Pencheva2, Alexander Oscar3, Radka Kаneva2 1 – University Pediatric Hospital Sofia, Screening and Functional Endocrine Diagnostics, Medical University Sofia, Bulgaria; 2 – Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University Sofia, Bulgaria; 3 – Department of Ophthalmology, University Hospital Alexandrovska, Medical University Sofia, Bulgaria Abstract:Тheseptooptic dysplasia (SOD) is an extremely heterogeneous condition. The classical triad includes optic nervehypoplasia/aplasia, midline defects, and hypopituitarism. Anomalies of the visual system, CNS, and various systemsmay also be observed. Classically, mutations in HESX1 gene are associated with SOD, but other genes are also involved in the etiology: SOX2, SOX3, FGF8, FGFR1, PROK1, PROKR, SHH. We present a patient with SOD and 7q11.23 microduplication syndrome. Case report. A boy, presented at 8.7 years, with short stature (SDSh-3.46). The examination reviled: mild mental retardation, developmental delay, mutism, hearing loss, cleft lip and palate, partial IGHD (peak GH 4.1 mU/L), 4-years delayed BA, cryptorchidism, high degree hyperopia, astigmatism, cataracta, iris coloboma. APH (MRI). Methods. Direct sequencing of HESX1, SOX2, SOX3, array CGH was performed. Results. After negative screening of HESX1, SOX2, SOX3, four chromosomal aberrations were found by array CGH: 1. duplication in chr1:1р36.13, including the gene SPEN; 2. 698kb duplication in chr10:10p14-p13, involving the DHTKD1 gene; 3. 10:10q, including the genes DNA2, STOX1, KIAA1279.
    [Show full text]
  • Emerging Role of the Kinesin Family Member Genes in Birth Defects Silvia Kalantari ‍ ,1 Isabel Filges ‍ 1,2
    Developmental defects J Med Genet: first published as 10.1136/jmedgenet-2019-106769 on 19 May 2020. Downloaded from REVIEW ‘Kinesinopathies’: emerging role of the kinesin family member genes in birth defects Silvia Kalantari ,1 Isabel Filges 1,2 ► Additional material is ABSTRact The first kinesins were observed in the context published online only. To view, Motor kinesins are a family of evolutionary conserved of axonal transport in neurons, and a novel disease please visit the journal online proteins involved in intracellular trafficking of various entity of ‘motor–proteinopathy’ was proposed for (http:// dx. doi. org/ 10. 1136/ 4 jmedgenet- 2019- 106769). cargoes, first described in the context of axonal transport. the pathogenesis of axonal neuropathies in 2001. They were discovered to have a key importance in cell- Due to their role in cellular membrane trafficking, 1 Medical Genetics, Institute cycle dynamics and progression, including chromosomal however, kinesins are essential for the functioning of Medical Genetics and condensation and alignment, spindle formation and of many polar cell types, such as neurons, epithelial Pathology, University Hospital Basel and University of Basel, cytokinesis, as well as ciliogenesis and cilia function. cells, sperm cells or stem cells during organogen- Basel, Switzerland Recent evidence suggests that impairment of kinesins is esis. Kinesins also play a fundamental role in cell- 2Department of Clinical associated with a variety of human diseases consistent cycle dynamics, both during mitotic
    [Show full text]